SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference

    TSX symbol: SBS

    CALGARY, June 11 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), a
biotechnology company developing insulin and other metabolic and
cardiovascular protein-based pharmaceuticals and a series of
non-pharmaceutical products, today announced that its President and CEO,
Andrew Baum, is scheduled to present an overview of the Company's operations
including an update on its proprietary oilbody-oleosin technology at the
Needham & Company, LLC Sixth Annual Biotechnology and Medical Technology
Conference. The presentation is scheduled for 10:30 AM Eastern Time on
Thursday June 14, 2007 at the New York Palace Hotel in New York City.
    Interested parties may access the live webcast by visiting the Company's
website at Please connect at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may be
required to join the webcast. An audio archive of the presentation will be
available for approximately 30 days.

    About SemBioSys Genetics Inc. (

    Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company
developing insulin and other protein-based pharmaceuticals for metabolic and
cardiovascular diseases. The Company's lead candidate is recombinant human
insulin produced in the plant host safflower, to serve the rapidly expanding
global diabetes market and to supply insulin for inhalation and other
alternative insulin delivery technologies. The Company's other protein-based
pharmaceutical candidate is a cardiovascular drug called Apo AI. SemBioSys is
also developing a series of non-pharmaceutical products addressing animal and
aquaculture health, nutritional oils and human topical markets.

    This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including, but not
limited to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time-to-time in the Company's ongoing filings with the Canadian securities
regulatory authorities which filings can be found at Given
these risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statements either
as a result of new information, future events or otherwise, except as required
by applicable Canadian securities laws.
    %SEDAR: 00020947E

For further information:

For further information: SemBioSys Genetics Inc., Mr. Andrew Baum,
President and Chief Executive Officer, Phone: (403) 717-8767, Fax: (403)
250-3886, E-mail:, Internet:; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail:

Organization Profile

SemBioSys Genetics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890